Back to results
US 7,351,721 B2Granted
Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
AssigneeOno Pharmaceutical Co., Ltd.
InventorsTakuya Seko, Masashi Kato
Life of this patent
Estimating the term…
Abstract
The present invention relates to the compounds of the formula (I) and salts thereof (all the symbols are the same meanings as described in the specification). The compounds of the formula (I) possess inhibitory activity of N-type calcium channel, so they are useful as drug for prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis, epilepsy, asthma and pollakiuria etc. or agent for the treatment of pain.
Claims11
An amino acid compound of formula (I)
- wherein,
- R1 is C1-15 alkyl, C1-8 alkoxy, phenyl, C3-8 cycloalkyl, C1-4 alkyl substituted with phenyl or C3-8 cycloalkyl, C1-4 alkoxy substituted with phenyl or C3-8 cycloalkyl, or C2-4 alkenyl substituted with phenyl or C3-8 cycloalkyl,
- wherein all the said phenyl and C3-8 cycloalkyl in R1 may be substituted with 1-3 substituent(s) selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, phenyl, phenoxy, benzyloxy, —SR5 (in which R5 is hydrogen or C1-4 alkyl), C2-5 acyl, halogen, C1-4 alkoxycarbonyl, nitro and —NR6R7 (in which R6 and R7 are independently, hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl),
- A is —CO—,
- R2 is hydrogen,
- D is C1-4 alkylene,
- E is —O—, —S—, —SO—, or —SO2—,
- R3 is carbocyclic ring or C1-4 alkyl substituted with carbocyclic ring,
- wherein the carbocyclic ring in R3 may be substituted with 1-3 substituent(s) selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, phenyl, phenoxy, benzyloxy, —SR13 (in which R13 is hydrogen or C1-4 alkyl), C2-5 acyl, halogen, C1-4 alkoxycarbonyl, nitro and —NR14 R15 (in which R14 and R15 are independently, hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl),
- J is J1 or J2,
- J1 is —O— or —NR16— (in which R16 is hydrogen or C1-4 alkyl),
- J2 is NR17— (in R17 alkyl substituted with phenyl), NR18R19 (in which R18 and R19 are independently, hydrogen or C1-4 alkyl), hydroxy, C1-4 alkoxy, —(C1-4 alkylene)-OH, —(C1-4 alkylene)-O—(C1-4 alkyl), —(C1-4 alkylene)-O—(C2-5 acyl), —NR20—NR21— (in which R20 and R21 are independently, hydrogen or C1-4 alkyl which may be substituted with one phenyl), —NR22—(C1-4 alkylene)-NR23— (in which R22 and R23 are independently, hydrogen or C1-4 alkyl which may be substituted with one phenyl), —NR24—(C1-4 alkylene)-O— (in which R24 is hydrogen or C1-4 alkyl which may be substituted with one phenyl) or —NR25—(C1-4 alkylene)-S— (in which R25 is hydrogen or C1-4 alkyl which may be substituted with one phenyl),
- R4 is R4-1, R4-2 or R4-3,
- R4-1 is piperidinyl which may be substituted with 1-3 substituent(s) selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, phenyl, phenoxy, benzyloxy, —SR29 (in which R29 is hydrogen or C1-4 alkyl), C2-5 acyl, halogen, 1-4 alkoxycarbonyl, nitro and —NR30R31 (in which R30 and R31 are independently, hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R30 and R31 taken together with nitrogen atom to which they are attached represents 5-7-membered saturated heterocyclic ring necessarily containing one nitrogen atom and optionally further containing one nitrogen atom or one oxygen atom),
- R4-2 is piperidinyl, which is substituted with one hydroxy or one —O—(C1-4 alkylene)-O—(C1-4 alkyl) and may be substituted with further 1-2 substituent(s) selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, phenyl, phenoxy, benzyloxy, —SR35 (in which R35 is hydrogen or C1-4 alkyl), C2-5 acyl, halogen, C1-4 alkoxycarbonyl, nitro, —NR36R37 (in which R36 and R37 are independently, hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R36 and R37 taken together with nitrogen atom to which they are attached represents 5-7-membered saturated heterocyclic ring necessarily containing one nitrogen atom and optionally further containing one nitrogen atom or one oxygen atom), hydroxy and —O—(C1-4 alkylene)-O—(C1-4 alkyl),
- R4-3 is -L-M, -L- is piperidinyl which may be substituted with 1-3 substituent(s),
- M is carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) (with the proviso that when the carbocyclic ring of said carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) is phenyl, said ring is substituted with at least one substituent(s), and that when the said heterocyclic ring of said carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) is 5-7-membered saturated heterocyclic ring in which the nitrogen atom in the said heterocyclic ring is bonded to group L shown as
- and which may contain further one nitrogen atom or one oxygen atom, then such a ring is substituted with at least one substituent(s)), C1-4 alkyl substituted with 1-2 substituent(s) selected from the group consisting of carbocyclic ring which may be substituted with 1-3 substituent(s), and heterocyclic ring which may be substituted with 1-3 substituent(s), —O-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s)) (with the proviso that when the carbocyclic ring of said —O-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) is phenyl, said ring is substituted with at least one substituent(s)), —S-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 of substituent(s)), —NR38-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 of substituent(s)) in which R38 is hydrogen or C1-4 alkyl which may be substituted with one phenyl, —O—CH2-(carbocyclic ring which may be substituted with 1-3 of substituent(s)) (with the proviso that when the carbocyclic ring of said —O—CH2-(carbocyclic ring which may be substituted with 1-3 of substituent(s) is phenyl, said ring is substituted with at least one substituent(s)), —O—(C2-4 alkylene)-(carbocyclic ring which may be substituted with 1-3 of substituent(s)), —O—(C1-4 alkylene)-(heterocyclic ring which may be substituted with 1-3 of substituent(s)), —S—(C1-4 alkylene)-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 of substituent(s)), —NR39-4 alkylene)-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s)) (in which R39 is hydrogen, C1-4 alkyl which may be substituted with one phenyl or C2-5 acyl which may be substituted with 1-3 of halogen) or —CO-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s)), wherein the substituent(s) of the carboxylic ring and heterocyclic ring in L and M are selected from C1-4 alkyl, C2-4 alkenyl, hydroxy, C1-4 alkoxy, —(C1-4 alkylene)-OH, —O—(C1-4 alkylene)-O—(C1-4 alkyl), halogen, —NR40R41 (in which R40 and R41 are independently, hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R40 and R41 taken together with nitrogen atom to which they are attached represents 5-7-membered saturated heterocyclic ring necessarily containing one nitrogen atom and optionally further containing one nitrogen atom or one oxygen atom), SR42 (in which R42 is hydrogen or C1-4 alkyl), nitro, trifluoromethyl, C1-4 alkoxycarbonyl, oxo and C2-5 acyl, with the proviso that when J is J1, R4 does not represent R4-1,
- or a pharmaceutically acceptable salt thereof.
16 more elements
Dependencies are inferred from the claim text.